blue cross semaglutide Blue Shield to stop covering popular weight-loss drugs IBX parent company posts $239M
Description
The present study aims to investigate whether semaglutide, a long-acting GLP1R agonist, can ameliorate cardiac hypertrophy induced by pressure overload, and explore the potential mechanism
A total of 902 patients received once-weekly subcutaneous semaglutide during the run-in phase of the research
( Figure 6 )
Anyone using the 2.4 mg weekly injection privately can move directly to the 25 mg daily tablet, and the MHRA confirmed this transition pathway at approval
Safety was consistent with the known profile of semaglutide
Your insights could help others on their journey to better health
